Kenvue (KVUE) Q2 FY2026 Earnings Preview

Report date: Thursday, August 6, 2026, before market open (no conference call)

The Setup

Kenvue reports fiscal second-quarter 2026 results tomorrow morning, but this will be an unusually quiet print: Kenvue won't host its usual quarterly conference call due to the pending merger, limiting the company's ability to provide color on the results or address investor questions. With the Kimberly-Clark acquisition dominating the story, the release itself — and any incremental deal/litigation commentary — will matter more than usual.

Consensus Expectations

• EPS: Kenvue is slated to report second-quarter 2026 results on Aug. 6, before market open... For revenues, the consensus mark is pegged at $4 billion, implying a rise of 3.9% from the year-ago quarter. The Zacks Consensus Estimate for the company's earnings is pegged at 32 cents per share, which reflects an increase of 10.3% from the year-ago quarter's figure.
• Some estimate providers (Reuters/LSEG-sourced) show slightly higher numbers, with analysts expect the maker of Tylenol, Band-Aid and Neutrogena to post earnings per share of $0.35, up from $0.32 in the first quarter.
• Track record: the company delivered an earnings surprise of 18.5% last quarter, and its earnings beat the Zacks Consensus Estimate by 12.1%, on average, in the trailing four quarters. However, Zacks' quantitative model is not flagging a beat this time, as Kenvue currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.

Where the Business Stands Coming In

Kenvue's turnaround has been gaining traction after a rough patch. Q1 FY2026 (reported May 7) was a strong data point: Kenvue kicked off fiscal 2026 on a strong note, reporting first-quarter net sales of $3.91 billion, up 4.5% year over year, supported by 0.7% organic sales growth and favorable pricing. Improved operating efficiency and global supply chain optimization helped lift the company's adjusted gross margin to 60.8%, fueling a 33% year-over-year jump in adjusted EPS to $0.32, well ahead of Wall Street's expectation of $0.27 per share. That followed a genuinely difficult Q2 FY2025, when a leadership shake-up and disappointing execution (organic sales -4.2%, adjusted EPS $0.29) triggered the board's strategic review that ultimately produced the Kimberly-Clark deal.

Segment dynamics to watch: - Skin Health & Beauty has been the standout. Growth was led by the Skin Health and Beauty segment, which delivered 5% organic sales growth in Q1, and per pre-earnings coverage, the performance of Kenvue's Skin Health and Beauty division will be critical — it was the company's strongest growth business in the first quarter, with net sales rising 8.4% and organic sales increasing 5%, driven by Neutrogena's expansion and new product launches from OGX. Investors will look for evidence that momentum extended into the second quarter. - Self Care remains the soft spot. The company has been witnessing weakness in its Self Care business for a while. The business remains exposed to unpredictable cold, flu and allergy seasons, which can create volatility in demand. Weak seasonal incidence across major markets has been hurting results, highlighting the segment's dependence on external health patterns. A partial offset/catalyst: Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue's Self Care portfolio, potentially strengthening the Tylenol brand's position in the competitive pain relief category — though it's too early to show up meaningfully in Q2 numbers given the late-July approval. - Margins/restructuring: Kenvue's board approved a new 2026 Restructuring Initiative (on top of the prior multi-year program) aimed at supply-chain and operating-model simplification, with margin expansion remaining a key focus as Kenvue works through a strategic restructuring expected to generate approximately $250 million in pre-tax charges for fiscal 2026.

No Guidance — the Merger Overhang

Because of the pending Kimberly-Clark transaction, Kenvue has stopped providing forward guidance (as it noted in Q1) and won't host a call tomorrow. Deal mechanics and status:

• Terms: each share of Kenvue common stock... will be converted into the right to receive (i) 0.14625 shares of Kimberly-Clark common stock... plus (ii) $3.50 in cash... In total, we expect approximately 280 million shares of common stock to be issued and approximately $6.7 billion to be paid for the Merger Consideration.
• Approvals so far: Shareholders of both companies approved the deal in January 2026, and the waiting period applicable to the Kenvue Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act expired on February 4, 2026. Completion... remains subject to the satisfaction of other customary closing conditions... including the receipt of foreign regulatory approvals. More recently, Kimberly-Clark's intended acquisition of Kenvue has been cleared by the European Commission under the terms of the Foreign Subsidies Regulation... The deal, due to close in the second half of 2026, still needs merger approval from the EU regulator.
• Termination fee: The Merger Agreement also provides for certain termination rights, and under certain specified circumstances, both Kimberly-Clark and Kenvue may be required to pay the other a termination fee of $1.1 billion.
• Timing: Management continues to guide toward a second-half 2026 close, pending remaining EU merger clearance and other customary conditions.

Risk to Watch: Revived Tylenol Litigation

A meaningful overhang re-emerged in mid-July: a federal appeals court on Monday revived more than 500 private lawsuits against Tylenol maker Kenvue over the painkiller's alleged link to autism. Kenvue continues to dispute the underlying science — Kenvue maintained that Tylenol is safe, and said the decision "does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder." Still, the ruling is a blow to Kenvue, which likely will face thousands of new lawsuits that could cost the company billions and adds a fresh layer of uncertainty investors will want addressed in the release's risk-factor language, even without a call to ask questions directly.

Stock, Valuation, and Sentiment

• KVUE shares have recovered from their 2025 lows but remain well below pre-strategic-review levels: shares closed around $19.66 on August 5, near their 1 year low of $14.02 and a 1 year high of $22.22.
• Deal arbitrage: with KMB near $112.40 and the fixed exchange ratio ($3.50 cash + 0.14625 KMB shares), the implied deal value is roughly $19.94/share — putting KVUE trading close to (~1–1.5% below) takeout value, consistent with Wall Street analysts rat[ing] the stock a hold, with a mean price target of $19.83 implying modest upside of 1.45% from the current price of $19.55.
• Analyst stance is mixed-to-cautious: Zacks Research lowered Kenvue from a "strong-buy" rating to a "hold" rating on July 7; Barclays upped their price target from $18.00 to $19.00 (equal weight) on July 21; Citigroup lowered their price objective from $20.00 to $19.00 (neutral) in April; Weiss Ratings raised shares to "hold (c)" in June; Wall Street Zen upgraded to "buy" on July 12. Overall, three equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating.
• Dividend: Kenvue continues paying its quarterly dividend through the pending deal — the company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This is an increase from Kenvue's previous quarterly dividend of $0.21 (i.e., held flat at $0.21).

What to Watch in Tomorrow's Print

1. Organic sales trajectory — Did the sequential improvement seen in Q1 (+0.7%) continue or accelerate, especially given a presumably better cold/allergy season comp than the weak year-ago period?
2. Skin Health & Beauty momentum — Can Neutrogena/OGX-led growth sustain ~5% organic growth, or decelerate?
3. Self Care/Tylenol — Early read (if any) on Tylenol with Naproxen distribution, plus commentary (in the release, absent a call) on litigation exposure following the July appellate ruling.
4. Margins — Gross/operating margin trends given ongoing 2026 Restructuring Initiative charges (~$250M full-year) and tariff/input cost commentary.
5. Merger-related costs and disclosures — Any update on regulatory approval timeline (EU merger clearance still pending) or acquisition-related expenses; KMB's own Q2 10-Q disclosed rising acquisition-related costs, so watch for parallel commentary from Kenvue.
6. Balance sheet/cash flow — Free cash flow trends and net debt (~$7.6B) heading into a deal that will layer on new financing at the KMB level.

Given the absence of a call and no forward guidance, the market's reaction will likely hinge on (a) whether results beat/miss the ~$0.32 EPS / ~$4.0B revenue consensus, (b) segment-level trends in Skin Health & Beauty vs. Self Care, and (c) any language on deal timing or litigation risk — with the stock's trading behavior increasingly tethered to the KVUE/KMB arbitrage spread rather than standalone fundamentals.